FDA finally gets a map of the supplement aisle—and what's actually in it
H.R. 8370 — Dietary Supplement Listing Act of 2026 · Filed by Maxine Dexter (D-OR) · Introduced Apr 20, 2026 · Referred to committee
Your members of Congress
Enter a ZIP to see where your representative and both senators stood on this bill.
Looked up on this device — your ZIP is never stored on our servers.
What it does
This bill requires dietary supplement manufacturers to register their products with the FDA by submitting detailed information including ingredients, labels, warnings, and manufacturing locations. Supplements already on the market have 18 months to register; new products must register before sale. The FDA will create a public database of this information (with some proprietary blend details kept confidential) and assign each product a listing number that must appear on labels.
Why we flagged it
The bill's core mechanism is a mandatory registration and listing system for dietary supplements sold in the US, with public disclosure of most product information. This is a regulatory transparency and traceability measure, not a ban or approval requirement.
What the text implies
- Proprietary blend ingredient amounts remain confidential, limiting consumer transparency on the most opaque aspect of supplement formulations and potentially preserving competitive secrets over full disclosure.
- The 18-month compliance window for existing products may create a temporary enforcement gap during which non-compliant products remain on shelves without penalty until the deadline passes.
The full analysis lists 4 implications of this text.
Who stands to gain
dietary supplement manufacturers (large firms with compliance infrastructure); FDA contractors (database development and management); US-based supplement distributors and agents